Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROME Trial: Personalized Therapy vs SoC
NCT04591431Phase 2Unknown
- Sponsor
- Fondazione per la Medicina Personalizzata
- Start
- Oct 2020
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib, trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib and 20 more in breast cancer, gastrointestinal cancer, non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Fondazione per la Medicina Personalizzata. Primary endpoint: Overall Response Rate at 42 months. Status: unknown.
02
Drugs
03
Conditions
breast cancergastrointestinal cancernon-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04591431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591431.